Cidofovir

Safrin, Sharon; Cherrington, Julie M.; Jaffe, Howard S.

doi:10.1007/978-1-4615-4743-3_10

Cited by 46 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prophylactic volume expansion has been shown to prevent harm from amphotericin B, antivirals including foscarnet, cidofovir and adefovir [81–83] as well as drugs causing crystal nephropathy such as indinavir, acyclovir, and sulfadiazine [84]. …”

Section: Volume Expansionmentioning

confidence: 99%

Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017

et al. 2017

View full text Add to dashboard Cite

BackgroundAcute kidney injury (AKI) in the intensive care unit is associated with significant mortality and morbidity.ObjectivesTo determine and update previous recommendations for the prevention of AKI, specifically the role of fluids, diuretics, inotropes, vasopressors/vasodilators, hormonal and nutritional interventions, sedatives, statins, remote ischaemic preconditioning and care bundles.MethodA systematic search of the literature was performed for studies published between 1966 and March 2017 using these potential protective strategies in adult patients at risk of AKI. The following clinical conditions were considered: major surgery, critical illness, sepsis, shock, exposure to potentially nephrotoxic drugs and radiocontrast. Clinical endpoints included incidence or grade of AKI, the need for renal replacement therapy and mortality. Studies were graded according to the international GRADE system.ResultsWe formulated 12 recommendations, 13 suggestions and seven best practice statements. The few strong recommendations with high-level evidence are mostly against the intervention in question (starches, low-dose dopamine, statins in cardiac surgery). Strong recommendations with lower-level evidence include controlled fluid resuscitation with crystalloids, avoiding fluid overload, titration of norepinephrine to a target MAP of 65–70 mmHg (unless chronic hypertension) and not using diuretics or levosimendan for kidney protection solely.ConclusionThe results of recent randomised controlled trials have allowed the formulation of new recommendations and/or increase the strength of previous recommendations. On the other hand, in many domains the available evidence remains insufficient, resulting from the limited quality of the clinical trials and the poor reporting of kidney outcomes.Electronic supplementary materialThe online version of this article (doi:10.1007/s00134-017-4832-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Volume Expansionmentioning

confidence: 99%

Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017

et al. 2017

View full text Add to dashboard Cite

show abstract

“…CDV is a monophosphate nucleotide analog [ 42 ]. Through cellular phosphorylation, it is converted into diphosphate (active) form and competitively inhibits the incorporation of deoxycytidine triphosphate (dCTP) into viral DNA by viral DNA polymerase [ 43 ]. As a result, it disrupts further chain elongation.…”

Section: Antiviral Drugs Against Hcmvmentioning

confidence: 99%

An Update on Current Antiviral Strategies to Combat Human Cytomegalovirus Infection

Panda

Parashar

Viswanathan

2023

Viruses

View full text Add to dashboard Cite

Human cytomegalovirus (HCMV) remains an essential global concern due to its distinct life cycle, mutations and latency. As HCMV is a herpesvirus, it establishes a lifelong persistence in the host through a chronic state of infection. Immunocompromised individuals are at risk of significant morbidity and mortality from the virus. Until now, no effective vaccine has been developed to combat HCMV infection. Only a few antivirals targeting the different stages of the virus lifecycle and viral enzymes are licensed to manage the infection. Therefore, there is an urgent need to find alternate strategies to combat the infection and manage drug resistance. This review will provide an insight into the clinical and preclinical antiviral approaches, including HCMV antiviral drugs and nucleic acid-based therapeutics.

show abstract

“…The discovery of acyclovir has stimulated extensive research in the synthesis of new acyclonucleosides in which the carbohydrate moieties are acyclic chains mimicking the sugar portion of naturally occurring nucleosides. Some acyclonucleosides containing chiral carbons in the acyclic side chain, such as S-HPMPC (Cidofovir), S-HPMPA, R-PMPA (Tenofovir), S-DHPA, et al, have been shown to possess antiviral activities (Figure ). The biological activity spectrum of the acyclic nucleoside is markedly influenced not only by the base moiety, but also by the structure and absolute configuration of the aliphatic side chain.…”

mentioning

confidence: 99%

Synthesis of Acyclic Nucleosides with a Chiral Amino Side Chain by the Mitsunobu Coupling Reaction

Guo

Niu

et al. 2010

J. Org. Chem.

View full text Add to dashboard Cite

show abstract

Cidofovir

Cited by 46 publications

References 43 publications

Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017

Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017

An Update on Current Antiviral Strategies to Combat Human Cytomegalovirus Infection

Synthesis of Acyclic Nucleosides with a Chiral Amino Side Chain by the Mitsunobu Coupling Reaction

Contact Info

Product

Resources

About